2017 Dermatology Coding Updates

2017 Spring Current Concepts
in Dermatology Seminar
American Osteopathic College of Dermatology
March 31, 2017

Faith C M McNicholas, RHIT, CPC, CPCD, PCS, CDC
Manager, Coding and Reimbursement
American Academy of Dermatology
mcnicholas@aad.org

2017 CPT News

<table>
<thead>
<tr>
<th>CPT/LOC</th>
<th>Modifier Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telemedicine: Appendix P</td>
<td>*99201 - *99215</td>
<td>Lists current CPT codes with evidence of some payer approval for use when provided via integrative audio and video telecommunication system</td>
</tr>
<tr>
<td>*</td>
<td>*</td>
<td>*E/M codes included in this list</td>
</tr>
<tr>
<td>Modifier 95</td>
<td>*</td>
<td>Check local carrier policy on coverage</td>
</tr>
<tr>
<td>0419T</td>
<td>(will sunset January 2022)</td>
<td>Destruction of neurofibroma, extensive (cutaneous, dermal extending into subcutaneous); face, head and neck, greater than 50 neurofibromas</td>
</tr>
<tr>
<td>04120T</td>
<td>(will sunset January 2022)</td>
<td>Trunk and extremities, extensive, greater than 100 neurofibromas</td>
</tr>
</tbody>
</table>

2017 Medicare Part B Premium and Deductible

- 2017 Part B premium standard is $134
  - Average is $109, up from $104 in 2016
- Low Social Security cost of living adjustment of 0.3%
  - "Hold harmless" provision designed to protect seniors prevented a larger increase
- 2017 Part B Deductible is $183, up from $166 in 2016
  - Co-insurance remains 20% of Medicare Physician Fee Schedule (MPFS) allowed amount
- File Medicaid claim prior to billing patient
Medicare Beneficiary Identifier Revision

By April 2019 Medicare beneficiaries, Social Security ID numbers will be replaced with random identifiers.

**CMS requests provider’s assistance**

- Check your patient’s address
- Ask the patient to update the Social Security Office directly if any changes

https://faq.ssa.gov/ics/support/KBAnswer.asp?questionID=3704

Administrative Law Judge (ALJ) and Federal Claim Appeal Increase

**ALJ and Federal District Court amount in controversy increase for 2017**

<table>
<thead>
<tr>
<th>Appeal Claim Total Required</th>
<th>Administrative Law Judge</th>
<th>Federal District Court</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>$150</td>
<td>$1,500</td>
</tr>
<tr>
<td>2017</td>
<td>$160</td>
<td>$1,560</td>
</tr>
</tbody>
</table>

*Total may encompass a single claim or the accumulation of claims

Medicare Drug Waste Modifier

**Medicare Change Request CR 9603**

**JW** - Drug amount discarded/not administered to any patient, Documentation must be available if requested

- Beginning January 1, 2017
- Reporting unused drug and biological portions require JW modifier to identify discarded drugs and biologicals when processing Part B claims.
- Do not use JW modifier to report Competitive Acquisition Program (CAP) drugs and biologicals.
Medicare Drug Waste Modifier

Documentation must include
- Date and time the drug was discarded
- Amount discarded
- Reason for wastage
- Who wasted the drug

Check local Medicare contractor for provider requirements for reporting of drug wastage

For more information see:
- Derm Coding Consult, Spring 2015, Billing for Drugs and Biologicals in your Practice

Medicare Payment Revision

Non-face-to-face prolonged E/M service

- Must be
  - Tied to an E/M service
  - Time spent by billing physician only
  - Not within the scope of clinical staff
  - No other CPT to report this work

- Document
  - Time
  - Summary of non-face-to-face work

Prolonged E/M Service

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Global</th>
<th>CMS work RVU</th>
</tr>
</thead>
<tbody>
<tr>
<td>99358</td>
<td>XXX</td>
<td>2.10</td>
</tr>
<tr>
<td>99359</td>
<td>XXX</td>
<td>1.00</td>
</tr>
</tbody>
</table>
2017 Medicare Fee Schedule Overview

• Published on 11/15/2016
• Very little impact on dermatology payments overall
• CMS estimates the CY 2017 PFS conversion factor (CF) to be $35.8887, a slight increase over the 2016 CF of $35.8043.

2017 Medicare Fee Schedule Overview - overview

• Reflectance Confocal Microscopy (RCM) 96931-96936 assigned new assigned values.
• No more Physician Quality Reporting System or EHR Meaningful Use reporting.
• Instead, MACRA Quality Payment Program (QPP) with a Merit-based Payment Improvement System (MIPS) and Alternate Payment Models (APMs).
Two Tracks: MIPS and Advanced APMs

MIPS Options

- Test the program — report on a limited set of data to avoid penalties only
- Partial participation — report more data for at least 90 days to receive a small incentive
- Full participation — report all elements for 90 days or more to receive full incentive

Advanced APM Option

- Join an Advanced APM
  - Most receive 25% of Medicare Part B payments or see 20% of Medicare Part B patients through an advanced APM in 2017
  - Potential to earn a 5% incentive payment in 2019

MACRA Timeline

2017 is a Transition Year — Pick Your Pace

Test Pace: Avoid Penalties

- Report ONE of the following:
  - One measure in the quality performance category at least once
  - One activity in the improvement activity category
  - Two required measures making up the base score of the advancing care information (ACI) category

Partial Participation: Small Incentive

- Report ONE of the following for 90 days:
  - More than one measure in the quality performance category
  - More than one improvement activity
  - More than the five required measures in the ACI category

Full Participation: Larger Incentive

- Report ALL of the following for 90 days:
  - Six quality measures in the quality performance category
  - One high-weighted improvement activity or two medium-weighted improvement activities
  - Five required measures making up the base score of the ACI category.

*The AAD strongly recommends practices report more than one measure or report at least one measure over a 90-day period to ensure an inclusion policy in their area of assessment, goal or measurement. Failure to comply in any measure in April of 2017 will result in a penalty in 2019.
Review of Codes with 10 and 90 Day Global Days

- Physicians in Florida, Kentucky, Louisiana, Nevada, New Jersey, North Dakota, Ohio, Oregon, and Rhode Island will be expected to report post-procedure visits using CPT 99024 beginning July 1.

- North Carolina — exempt but can volunteer
- Practices with fewer than 10 providers are exempt.
- Codes reported annually by more than 100 practitioners and reported more than 10,000 times, or allowed charges in excess of $10 million annually
- No penalty for not reporting, no payment for reporting

CMS GLOBAL SURGERY DATA COLLECTION CODE LIST
Review of Codes With 10 and 90 Day Global Periods

- CMS survey practitioners to gain information regarding post-op visits may occur in mid-2017
- CMS will collect data from Pioneer and Next Gen ACOs on the "activities and resources involved in and around surgical events"

ICD 10 Updates

- Code specificity required as of October 1, 2016
- No specific dermatology code changes. However, 2017 Guideline changes may impact your practice
- Review Derm Coding Consult for more information

<table>
<thead>
<tr>
<th>FALL 2016</th>
<th>WINTER 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nothing lasts forever - ICD-10 code freeze and specificity safe harbor ends</td>
<td>No dermatology specific ICD-10 CM code changes for 2017</td>
</tr>
</tbody>
</table>

2017 ICD-10 Guidelines

- Clinical Criteria and Code Assignment
- Excludes 1
- Bilateral Conditions
- Etiology/Manifestation
- Terms – With, Use additional code
- Episode of Care
- Complications of Care
Clinical Criteria / Code Assignment

• Diagnosis codes reported are NOT selected based on clinical criteria used to establish the diagnosis

• Physician’s statement alone that the condition is present supports reporting of the ICD-10 code.

Excludes1

• Listed with mutually exclusive codes:
  • Two conditions cannot be reported together
    • Clinically
    • Coding rule

• Clarification provided by CMS in October 2015
  • If unrelated, report both conditions

Example

Pathology Report
#1 specimen from abdomen – Lentigo maligna
#2 specimen from back – Malignant melanoma

ICD codes
D03.59 Melanoma in situ of other parts of trunk
C43.59 Malignant melanoma of other parts of trunk

Excludes1 melanoma in situ (D03.-)

Report both codes
Documentation must reflect separate sites within same anatomic location – per ICD grouping
### Bilateral conditions

- When available, report bilateral conditions with bilateral codes
- Even when only unilateral treatment is provided

<table>
<thead>
<tr>
<th>Bilateral Condition Is:</th>
<th>Treatment is:</th>
<th>Code as:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present bilaterally</td>
<td>Unilateral</td>
<td>Bilateral</td>
</tr>
<tr>
<td>Present bilaterally</td>
<td>Bilateral</td>
<td>Bilateral</td>
</tr>
<tr>
<td>Present unilaterally</td>
<td>Previously treated side is healed or no longer present</td>
<td>Unilateral – list side treated if applicable; History of code for previously treated side</td>
</tr>
</tbody>
</table>

### Bilateral Conditions

Patient presents with swelling and pain of both ears. On exam, manipulation of auricle causes pain and a furuncle is present at left pre-auricle area.

Gentle debridement of both ears and neomycin applied.

**Assessment:** otitis externa cellulitis

**Rx:** hydrocortisone drops.

**ICD-10-CM:** H60.13 Cellulitis of external ear, bilateral

Patient returns in follow-up of otitis externa cellulitis. Patient states right side is better, left still hurts.

Exam shows condition is resolved on right. Left side ear canal is red, swollen, and littered with moist, purulent debris.

**RX:** Continue hydrocortisone drops Ciprofloxacin 500 mg po bid for 10 days

**ICD-10-CM:** H60.12 Cellulitis of left external ear

### Etiology / Manifestation

Condition with underlying etiology and manifestations

- Sequencing rules apply
  - Underlying condition or cause is listed first
  - Manifestation of this condition or cause is listed second

- Code first/Use additional code
  - Links cause or etiology to condition being treated
  - May help to show complexity of care needed
Directional Terms - Updated

- Watch for “code first” and “use additional code” guidance
  L51 – Erythema multiforme
  Use additional code for adverse effect, if applicable, to identify drug
- “If applicable” was added to guidance for 2017

Example

Combination Code

75 year-old Type 1 diabetic female patient presents with small raised, yellow and somewhat waxy lesions on lower part of her legs.

Final Diagnosis: Necrobiosis lipoidica diabeticorum

ICD-10-CM code: E10.620 Type 1 DM with diabetic dermatitis

Example

One Condition / Two Codes

Patient presents for follow-up of non-pressure chronic ulcer of right ankle secondary to Type 1 diabetes. Breakdown of ulcer is limited to skin. Diabetes is followed by primary care.

Final diagnosis: non-pressure ulcer, DM type 1

ICD-10-CM codes:
- E10.621 Type 1 Diabetes mellitus with foot ulcer
  Use additional code to identify site of ulcer
- L97.311 Non-pressure chronic ulcer of right ankle limited to breakdown of skin
  Code first any associated underlying condition
Directional Term Updates

• With – as listed in code title or Alphabetic index
  
  \textit{L05.01 Pilonidal cyst with abscess}
  
• May be documented as “associated with” or “due to”

• Presumes causal relationship of linked terms

• Even in absence of documentation linking conditions

• If unrelated – Document as not related

Example

28 year old male presents with painful, swollen lesion in the sacrococcygeal region. Review of systems is negative for fever, chills or drainage at lesion site. \textbf{No abscess} is present at this time. Patient states that he had a similar lesion in the area approximately one year ago that disappeared spontaneously.

\textbf{Final Diagnosis:} Pilonidal cyst

\textbf{ICD-10-CM Code:} L05.91 Pilonidal cyst without abscess

Episode of Care - Clarification

• Initial care – A
  
  • Each encounter where active care is provided

• Subsequent care – D
  
  • Encounters occurring after active treatment is completed

Initial Care Includes

• Initial visit for the condition

• While patient is receiving active treatment for the condition

• Surgical treatment, emergency department encounter
Follow up patient for second degree caustic burns on back of right hand from drain cleaner. Doing well on steroids and topical medication. No signs of infection. Continue on current medications. Dressing changed, patient to return in two days for dressing change.

**ICD-10-CM Codes:**
- T23.661D Corrosion of second degree of back of hand, right
- T54.3X1D Toxic effect of corrosive alkalis and alkali-like substances, accidental

**Complications of Care**
- Based on documented relationship between condition and previous care or procedure
- Not all conditions occurring during or after procedures or treatment are considered complications
- Documentation must reflect cause-and-effect relationship
- Complication codes may reflect episode of care
- Active treatment – treatment of the condition described by the code

**Example**

Patient returns 5 days after punch biopsy with infection at biopsy site.

**ICD-10-CM Code:** T81.4XXA Infection following a procedure, initial encounter
Active Local Coverage Determination (LCDs)

- Allergy Testing
- Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds
- Debridement of Mycotic Nails
- Moh's Micrographic Surgery
- Removal of Benign Skin Lesions
- Surgical Treatment of Nails
- Treatment of Varicose Veins and Venous Stasis Disease of the Lower Extremities
- Wound Care

List is not conclusive – based on MAC
LCD Utilization and Limitations Guidelines

- Guidelines set out by Medicare
  - Discuss the conditions affected by the policy
  - List the conditions covered under the policy
  - Describe what constitutes medical necessity
  - Describe what can cause claim payment denial
- Usually found on the first page of the LCD
- Under Coverage Guidance

<table>
<thead>
<tr>
<th>Policy applies to</th>
<th>Reasons for non-coverage</th>
<th>Reasons for Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>SKs, Skin Tags, Wills, Milia, Molluscum contagiosum, Seb. epidermoid cysts, Rashes (new), Acquired hyperkeratotic keratoderma and Viral warts (excluding condyloma acuminatum)</td>
<td>Skin lesions that do not pose a threat to health or function is considered cosmetic and as such is not covered by the Medicare program.</td>
<td>Lesion has one or more of these characteristics: bleeding, intense itching, pain; Physical evidence of inflammation, e.g., purulence, oozing, edema, erythema; Obstructs an orifice or clinically restricts vision; In an anatomical region subject to recurrent physical trauma and there is documentation that such trauma has in fact occurred; Wart removals will be covered under all the above. In addition, if particular wart must be associated with chronic recurrent conjunctivitis Evidence of spread from one body area to another, particular evidence in patient.</td>
</tr>
</tbody>
</table>

Documentation

- Documentation in the medical record is critical in coding to ensure that every aspect of the patient condition and care is captured
- Use of the utilization and limitations guidelines can help improve your MR documentation
- Consider including words like:
  - Bleeding
  - Intense itching
  - Pain
  - Physical evidence of inflammation, e.g., purulence, oozing, edema, erythema
  - Obstructs an orifice or clinically restricts vision
  - Anatomical region subject to recurrent physical trauma
Documentation Example 1

A 17 y/o girl has a 1.1 cm raised brown nevus on her mid back that rubs on her bra. You remove it using a shave technique. Pathology report shows a benign compound nevus, and the lateral and underlying dermal margins are clear, confirming complete removal of the nevus.

You report:

11302 – shaving of epidermal or dermal lesion, single lesion, trunk, lesion diameter 1.1 – 2.0 cm

• Complete removal of this lesion does not make this an excision.

Documentation Example 2

82 yo female patient presents with linear, splayed, vertical patterns of lesions on her chest. States over time, they have increased, get caught in neck chain, are inflamed and causing pain. They started off light tan in color, but have progressed to becoming dark brown.

You report:

17110 – Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions

Documentation Example 3

A 1.2 cm flesh-colored polypoid nodule on the upper thigh of a 45 y/o man is irritated by his clothing. It is removed at the base with scissors, exposing underlying fat, and hemostasis is achieved with electrocautery. Pathology confirms a benign fibrofatty polyp.

You report:

11402 - Excision, benign lesion including margins, except skin tag, excised diameter 1.1 – 2.0 cm
Removal of Benign Lesion LCD

The LCD further states the following will allow coverage:

- If clinical diagnosis is uncertain, particularly where malignancy is a realistic consideration based on lesional appearance (e.g., non-response to conventional treatment, or change in appearance).
- Prior biopsy suggests or is indicative of lesion malignancy or premalignancy.

Documentation Example 4

50 yo boater has discreet but irregular 8mm shiny red flat lesion on his back. Clinical diagnosis is probable superficial BCC and a specimen is obtained for pathology with curettage as a definitive procedure with therapeutic intent to cure. Pathology confirms a benign diagnosis.

You report:

17110 – Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettage), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions

- If pt presented with more than 15 lesions, you would report 17111 – Destruction of benign lesions; 15 or more lesions

Novitas Solutions, Inc. (IMAC)

Local Coverage Determination (LCD): MOHS Micrographic Surgery (MMS) (L49861)

<table>
<thead>
<tr>
<th>Policy applicable to</th>
<th>Reason for non-coverage</th>
<th>Reason for Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOHS Micrographic Surgery (MMS)</td>
<td>Requires a single physician to act in 2 separate and distinct capacities: surgeon and pathologist</td>
<td>If either of these responsibilities is delegated to another physician or other qualified health care professional who reports the service(s) separately, the MMS codes should not be reported</td>
</tr>
<tr>
<td>CPT Codes: 17311 - 17315</td>
<td>Qualifications of the physician and office/facility team</td>
<td>The qualifications of the performing physician must be verifiable if requested by the Contractor</td>
</tr>
<tr>
<td>See AAD Appropriate Use Criteria (AUC)</td>
<td>Characteristics of the lesion (per procedure)</td>
<td>Providers of MOHS surgery are limited to MD or DO</td>
</tr>
<tr>
<td>See LCD Documentation Requirements section</td>
<td>Documentation of the Medical Necessity</td>
<td>The AUC provide necessary consideration of MOHS micrographic surgical treatment of a lesion</td>
</tr>
</tbody>
</table>
Medicare on Mohs

• After careful review, Medicare Jurisdictions adopted coverage for Mohs in accordance with the 2012 Appropriate Use Criteria (AUC) for Mohs Micrographic Surgery as published in *JAAD Volume 67, Issue 4, pp 531-550, October 2012*

• MMS appropriate only when:
  • Superficial (lateral) or deep margins of the cancer lesion are uncertain clinically.
  • Likelihood of surgical cure and reconstruction would be compromised without use of immediate microscopic examination of the surgical margins.

• The medical records should clearly show that MMS was chosen because of the complexity (e.g. poorly defined clinical borders, possible deep invasion, prior irradiation), size or location (e.g. maximum conservation of tumor-free tissue is important).

CMS MLN Matters® Number: SE1318

Guidance To Reduce Mohs Surgery Reimbursement Issues

(Appplies to all Medicare carriers)

• Documentation should support the medical necessity for Mohs procedure

• Operative notes and pathology documentation must clearly indicate:
  • That Mohs was performed using accepted MMS technique;
  • That physician acted in two integrated, but distinct, capacities as surgeon and pathologist;
  • That the location, number, and size of the lesion(s) treated;
  • That the number of stages performed; and
  • That the number of specimens per stage.

MLN Matters SE1318 Cont’d

Medicare Documentation Requirements

• Describe histology of the specimens taken in the first stage. Description should include:
  • Depth of invasion;
  • Pathological pattern;
  • Cell morphology; and, if present,
  • Perineural invasion or presence of scar tissue.

• Subsequent stages: note pattern and morphology of the tumor (if still seen) is as described for the first stage
  • Or, if differences are found, note the changes
Documentation Requirements Cont’d

• ICD-10-CM/CPT code(s) submitted must be supported in the medical record
• Documentation (pre-procedure E/M note and/or post-procedure operative notes) must address
  • Why the lesion will not be (was not) managed by standard excision or destruction technique and (when applicable)
  • Why (when utilized or referred to a plastic surgeon) procedures for complex repair, adjacent tissue transfer or rearrangement, flap, or graft codes are employed.

• Diagnosis is appropriate for MMS and that it is the appropriate choice for treating a particular lesion.
• The primary procedure options and repair options were discussed with the patient and clearly noted in the pre- or post- procedure documentation.
• Document why the lesion will not be (was not) managed by excision or destruction technique.
• MMS was performed using accepted MMS technique, in which the physician acts in two integrated and distinct capacities: surgeon and pathologist (therefore confirming that the procedure meets the definition of the CPT code(s)).

• Operative Note: document location, number, and size of the lesion(s); number of stages performed; number of specimens per stage
• Histology Note:  
  • First stage: if tumor present, depth of invasion; pathological pattern of the tumor; cell morphology; if present, note perineural invasion of scar tissue
  • Subsequent stages: if the tumor characteristics are the same as in the first stage, note this fact only. If the tumor characteristics are different from the first stage, describe the differences.
Mohs Micrographic Surgery
Appropriate Use Criteria

<table>
<thead>
<tr>
<th>Why was it developed?</th>
<th>AAD Appropriate Use Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Utilization of Mohs increased over 400% between 1995 and 2009</td>
<td><strong>• 270 indications</strong></td>
</tr>
<tr>
<td>• 1 in 4 skin cancers are treated with Mohs</td>
<td>• BCC</td>
</tr>
<tr>
<td>• Variation in use across the country</td>
<td>• SCC</td>
</tr>
<tr>
<td>• Allows specialty to ‘self-regulate’ and preserve the procedure for patients/tumors where benefit felt to be greatest;</td>
<td>• Lentigo maligna</td>
</tr>
<tr>
<td>• More AUC may be forthcoming</td>
<td>• Other rare cancers</td>
</tr>
<tr>
<td>• Oversight AUC Cmte proposed</td>
<td><strong>• 3 Areas of the Body</strong></td>
</tr>
<tr>
<td></td>
<td>• H—M—L</td>
</tr>
</tbody>
</table>

https://www.aad.org/practice-tools/quality-care/appropriate-use-criteria

AAD Definition of Appropriate

An appropriate treatment modality is one in which the anticipated clinical benefit combined with clinical judgment, exceeds the possible negative consequences for a specific indication.

- Anticipated clinical benefits of MMS may include high cure rate related to total margin assessment, low rate of recurrence, small defect size, range of reconstructive possibilities, retention of functional capacity, and low morbidity and mortality.
- Negative clinical consequences of MMS may include the possible risks of an extended surgical procedure under local anesthesia, risk of incorrectly interpreted margins, and risks associated with office-based surgery.
So What is Appropriate?

- Tumors in Area H and M are generally appropriate
- Smaller tumors in Area L (trunk & extremities) may not be appropriate
- Immunocompromised patients generally appropriate
- Recurrent tumors also generally appropriate in any location

Area H  
- Face, genitalia, hands, feet, nail units, scalp, interspaces, central face, eyelids, eyebrows, nose

Area M  
- Cheeks, forehead, scalp, neck, jawline, pretibial surface

Area L  
- Trunk and extremities excluding pretibial surface, hands, feet, nail units and ankles

Immunocompromised  
- HIV/AIDS, organ transplant, hematologic malignancy, or pharmacologic immunosuppression

Genetic Syndromes  
- Basal cell nevus syndrome, xeroderma pigmentosa, or other syndromes at high risk for skin cancer

Healthy  
- No immunosuppression, no prior radiation therapy to affected area, no chronic infections and no genetic syndromes that predispose to skin cancer

Prior Radiated Skin  
- Previously received therapeutic radiation to the area of interest

Aggressive features  
- Skin cancers having one or more of the following features have a higher incidence of local recurrence and regional metastasis and such that minimal margin excision may not be in the beneficiary’s best interest:
  - High tumor thickness
  - Ulceration
  - Deep invasion
  - Frequent regional lymph node involvement
  - Histologic atypia
Mohs Takeaway

- The physician (MD/DO) performing Mohs micrographic surgery must be specifically trained and highly skilled in MMS techniques and pathologic identification.
- If a surgeon performs an excision using Mohs surgical techniques but does not personally provide the histologic evaluation of the specimen(s), the CPT codes for MMS shall not be used.
  - Instead, standard excision codes should be chosen for such medically necessary services (e.g., 11600 – 11646).
- Medicare is aware that a biopsy of the skin lesion for which Mohs surgery is planned may be necessary in order for the physician to determine the exact nature of the lesion(s) to be removed. Occasionally, that biopsy may need to be done on the same day that the Mohs surgery is planned.
  - In order to allow separate payment for a biopsy and pathology on the same day as Mohs surgery, the -59 modifier is appropriate. The 59 modifier is also appropriate when a separate skin lesion, other than the lesion for which Mohs surgery is performed, is biopsied on the same day that the Mohs surgery is performed.

Mohs Takeaway

- If a prior biopsy of the site undergoing Mohs surgery has been previously performed within the last 60 days, the surgeon should make a reasonable effort to obtain those results rather than repeating the biopsy.
- Reporting both Mohs Micrographic Surgery CPT codes 17311-17315 and Surgical Pathology CPT® 88302-88309 on tissue used for margin evaluation during Mohs surgery is inappropriate and will indicate that true Mohs surgery was not done. Such claims for Mohs surgery (17311-17315) will be denied. There are occasional clinical situations in which tissue separate from the tissue examined during Mohs surgery is appropriately submitted for subsequent formalin fixed processing and histopathologic examination. The submitted tissue is not the same tissue that was processed during the Mohs surgery. It may constitute a tissue margin beyond that evaluated with Mohs surgery or it may involve a totally unrelated tissue specimen. In such situations both the Mohs surgery and the histopathology are subject to coverage. In such cases the clinical record must clearly show the reasoning for the histopathologic specimen and interpretation.
2017 Coding Packs – NEW!

AAD and AMA Coding Resources every practice needs in 2017!

ORDER NOW!
VISIT STORE.AAD.ORG

2017 Coding Webinar All-Access Pass

The 2017 Coding All-Access Pass gives you access to all 7 Live Webinars for new and experienced coders! Can’t attend at the box office? Don’t worry! The Webinar All-Access Pass also includes each corresponding On Demand webinar.

Start your coding! 2017 Live Webinars:
- Coding & Practice Updates for 2017 (Nov. 8, 2016)
- Code-Coding Updates 2017 (Jan. 12, 2017)
- Coding Guidelines for Compliance (Feb. 10, 2017)
- Coding: Awards and the Dollars You’re Entitled To (Apr. 17, 2017)
- Latest-Coding Hot Topics for Fall (Oct. 12, 2017)
- Ask the Coders (Oct. 19, 2017)

2017 Coding Webinar All-Access Pass Price: $299
Individual Live Webinars: $199 each

Visit store.aad.org

Coding Questions

Peggy Eiden - peiden@aad.org
Faith McNicholas - fmcnicholas@aad.org
Cynthia Stewart – cstewart@aad.org